Nuclisens Easyq Mrsa; Nuclisens Easyq Analyzer; Nuclisens Easyq Incubator (110 Volt); Nuclisens Director V.2.6
K102740 is the FDA 510(k) clearance record for NUCLISENS EASYQ MRSA; NUCLISENS EASYQ ANALYZER; NUCLISENS EASYQ INCUBATOR (110 VOLT); NUCLISENS DIRECTOR V.2.6, a class II device, cleared for bioMerieux, Inc. on under FDA product code NQX (System, Nucleic Acid Amplification Test, Dna, Methicillin Resistant Staphylococcus Aureus, Direct Specimen). FDA's definition for product code NQX reads: "A nucleic acid amplification assay system (including probes, other reagents, and instrumentation) is an aid in the identification of MRSA colonization status for the prevention and control of MRSA infections in healthcare settings". FDA records list 408 510(k) clearances for bioMerieux, Inc., from to . As of , FDA records show no recalls naming K102740.
Clearance record
- Decision date
- Received
- (240 days to decision)
- Product code
- NQX System, Nucleic Acid Amplification Test, Dna, Methicillin Resistant Staphylococcus Aureus, Direct Specimen
- Regulation
- 21 CFR 866.1640
- Device class
- Class II
- Review panel
- Microbiology
- Applicant
- bioMerieux, Inc. 100 Rodolphe St., Durham NC
- 510(k) summary
- Summary PDF
- Third party review
- No
Clearances, product code NQX
Trailing 12 monthsFDA records hold no clearances under product code NQX in the trailing twelve months.
Show the numbers
| Month | Clearances |
|---|---|
| December 2025 | 0 |
| January 2026 | 0 |
| February 2026 | 0 |
| March 2026 | 0 |
| April 2026 | 0 |
| May 2026 | 0 |
| June 2026 | 0 |
| July 2026 | 0 |
| August 2026 | 0 |
| September 2026 | 0 |
| October 2026 | 0 |
| November 2026 | 0 |
FIRST ARTICLE / WEEKLY
What cleared, what was recalled, and what changed in the standards. One edition a week for the people who make medical devices.
